Paul Francis Dellaripa, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Diseases, Interstitial | 42 | 2024 | 911 | 5.470 |
Why?
|
Arthritis, Rheumatoid | 33 | 2024 | 3763 | 2.410 |
Why?
|
Rheumatic Diseases | 7 | 2024 | 639 | 1.810 |
Why?
|
Rheumatology | 7 | 2024 | 611 | 1.210 |
Why?
|
Scleroderma, Systemic | 7 | 2024 | 344 | 1.070 |
Why?
|
Connective Tissue Diseases | 5 | 2019 | 286 | 0.930 |
Why?
|
Lung Diseases | 6 | 2019 | 1915 | 0.770 |
Why?
|
Idiopathic Pulmonary Fibrosis | 8 | 2022 | 502 | 0.770 |
Why?
|
Eosinophilic Granuloma | 2 | 2017 | 27 | 0.730 |
Why?
|
Autoimmunity | 2 | 2018 | 1370 | 0.680 |
Why?
|
Lung | 15 | 2024 | 9994 | 0.650 |
Why?
|
Climate Change | 1 | 2024 | 488 | 0.600 |
Why?
|
Myositis | 3 | 2024 | 269 | 0.580 |
Why?
|
Respiratory Sounds | 3 | 2017 | 697 | 0.550 |
Why?
|
Polyarteritis Nodosa | 2 | 2014 | 70 | 0.540 |
Why?
|
Autoimmune Diseases | 6 | 2024 | 2250 | 0.520 |
Why?
|
Infarction | 2 | 2014 | 248 | 0.510 |
Why?
|
Immunologic Factors | 2 | 2018 | 1588 | 0.450 |
Why?
|
Respiratory Function Tests | 10 | 2024 | 1683 | 0.430 |
Why?
|
Patient Care | 2 | 2022 | 624 | 0.400 |
Why?
|
Granuloma | 1 | 2013 | 327 | 0.360 |
Why?
|
Abdominal Pain | 2 | 2014 | 1063 | 0.360 |
Why?
|
Air Pollution | 1 | 2024 | 2317 | 0.360 |
Why?
|
Antirheumatic Agents | 7 | 2023 | 1374 | 0.350 |
Why?
|
Glucocorticoids | 6 | 2024 | 2145 | 0.320 |
Why?
|
Lung Transplantation | 3 | 2024 | 1305 | 0.310 |
Why?
|
Disease Management | 1 | 2018 | 2514 | 0.300 |
Why?
|
Matrix Metalloproteinase 7 | 3 | 2016 | 60 | 0.290 |
Why?
|
Eye Diseases | 1 | 2013 | 651 | 0.290 |
Why?
|
Sarcoidosis | 1 | 2013 | 520 | 0.290 |
Why?
|
Autoantibodies | 5 | 2022 | 2118 | 0.260 |
Why?
|
Myeloblastin | 2 | 2017 | 101 | 0.260 |
Why?
|
Pleurisy | 3 | 2013 | 54 | 0.260 |
Why?
|
Methotrexate | 4 | 2020 | 1719 | 0.250 |
Why?
|
Skin Diseases | 1 | 2013 | 1089 | 0.230 |
Why?
|
alpha 1-Antitrypsin | 2 | 2017 | 169 | 0.220 |
Why?
|
Humans | 81 | 2024 | 760621 | 0.210 |
Why?
|
Immunoglobulin A | 2 | 2019 | 979 | 0.210 |
Why?
|
Leadership | 1 | 2012 | 1371 | 0.200 |
Why?
|
Nervous System Diseases | 1 | 2013 | 1647 | 0.200 |
Why?
|
Kidney | 2 | 2014 | 7064 | 0.190 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 2 | 2015 | 288 | 0.190 |
Why?
|
Spirometry | 1 | 2024 | 924 | 0.190 |
Why?
|
Cardiomyopathies | 1 | 2013 | 1952 | 0.190 |
Why?
|
Erythema Induratum | 1 | 2000 | 3 | 0.180 |
Why?
|
Panniculitis, Nodular Nonsuppurative | 1 | 2000 | 7 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 13 | 2024 | 20509 | 0.180 |
Why?
|
Vital Capacity | 4 | 2024 | 965 | 0.180 |
Why?
|
Hypertension, Pulmonary | 2 | 2023 | 1570 | 0.180 |
Why?
|
Bronchiectasis | 1 | 2022 | 139 | 0.180 |
Why?
|
Lipoxygenase Inhibitors | 1 | 2000 | 93 | 0.180 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 2 | 2016 | 48 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 2282 | 0.170 |
Why?
|
Emphysema | 1 | 2022 | 240 | 0.170 |
Why?
|
Leukotriene Antagonists | 1 | 2000 | 123 | 0.170 |
Why?
|
Polymyositis | 2 | 2018 | 75 | 0.170 |
Why?
|
Disease Progression | 5 | 2024 | 13502 | 0.170 |
Why?
|
Hydroxyurea | 1 | 2000 | 282 | 0.160 |
Why?
|
Early Diagnosis | 1 | 2024 | 1180 | 0.160 |
Why?
|
Rheumatoid Factor | 1 | 2019 | 185 | 0.160 |
Why?
|
Macrophage Migration-Inhibitory Factors | 1 | 2018 | 109 | 0.160 |
Why?
|
Acetates | 1 | 2000 | 321 | 0.160 |
Why?
|
Giant Cell Arteritis | 2 | 2003 | 295 | 0.160 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2018 | 105 | 0.160 |
Why?
|
Dyspnea | 3 | 2023 | 1352 | 0.160 |
Why?
|
Dermatomyositis | 2 | 2019 | 256 | 0.150 |
Why?
|
Diagnosis, Differential | 9 | 2017 | 12965 | 0.140 |
Why?
|
Middle Aged | 38 | 2024 | 220352 | 0.140 |
Why?
|
Microscopic Polyangiitis | 1 | 2017 | 46 | 0.140 |
Why?
|
Attitude | 1 | 2022 | 777 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2017 | 67 | 0.140 |
Why?
|
Male | 45 | 2024 | 359744 | 0.140 |
Why?
|
Cough | 2 | 2017 | 595 | 0.140 |
Why?
|
Blood Sedimentation | 2 | 2014 | 234 | 0.130 |
Why?
|
Patients | 1 | 2022 | 906 | 0.130 |
Why?
|
Hot Temperature | 1 | 2022 | 1435 | 0.130 |
Why?
|
Prednisone | 2 | 2017 | 1565 | 0.130 |
Why?
|
Female | 45 | 2024 | 391270 | 0.130 |
Why?
|
Peroxidase | 2 | 2017 | 605 | 0.130 |
Why?
|
Anti-Asthmatic Agents | 1 | 2000 | 565 | 0.120 |
Why?
|
Forced Expiratory Volume | 2 | 2024 | 1809 | 0.120 |
Why?
|
Systemic Vasculitis | 1 | 2015 | 36 | 0.120 |
Why?
|
Osteopontin | 1 | 2016 | 302 | 0.120 |
Why?
|
Quinolines | 1 | 2000 | 759 | 0.120 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 506 | 0.120 |
Why?
|
Exercise Tolerance | 1 | 2020 | 830 | 0.120 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4166 | 0.120 |
Why?
|
Antibodies, Monoclonal | 3 | 2013 | 9185 | 0.120 |
Why?
|
Blood Proteins | 1 | 2020 | 1173 | 0.120 |
Why?
|
Asthma | 4 | 2017 | 6172 | 0.120 |
Why?
|
Pleural Diseases | 1 | 2015 | 137 | 0.120 |
Why?
|
Immunoglobulin E | 2 | 2017 | 1484 | 0.120 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 615 | 0.120 |
Why?
|
Adult | 29 | 2024 | 219994 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 792 | 0.110 |
Why?
|
Physicians | 1 | 2012 | 4591 | 0.110 |
Why?
|
Chemokine CXCL10 | 1 | 2015 | 316 | 0.110 |
Why?
|
Semaphorins | 1 | 2013 | 97 | 0.110 |
Why?
|
Citrulline | 1 | 2013 | 106 | 0.110 |
Why?
|
Epithelioid Cells | 1 | 2013 | 60 | 0.110 |
Why?
|
Autoantigens | 2 | 2017 | 877 | 0.110 |
Why?
|
Registries | 3 | 2020 | 8469 | 0.100 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 322 | 0.100 |
Why?
|
Risk Factors | 12 | 2022 | 74359 | 0.100 |
Why?
|
Panniculitis | 1 | 2012 | 45 | 0.100 |
Why?
|
Congresses as Topic | 2 | 2014 | 805 | 0.100 |
Why?
|
Subcutaneous Tissue | 1 | 2012 | 132 | 0.100 |
Why?
|
Internship and Residency | 1 | 2012 | 5870 | 0.100 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5785 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2648 | 0.090 |
Why?
|
Aged | 24 | 2024 | 169152 | 0.090 |
Why?
|
Smoking | 2 | 2024 | 9073 | 0.090 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2013 | 423 | 0.090 |
Why?
|
Heart Block | 1 | 2012 | 392 | 0.090 |
Why?
|
Mixed Connective Tissue Disease | 2 | 2024 | 32 | 0.090 |
Why?
|
Sjogren's Syndrome | 2 | 2024 | 235 | 0.090 |
Why?
|
Severity of Illness Index | 5 | 2023 | 15840 | 0.090 |
Why?
|
Lymphoma, T-Cell | 1 | 2012 | 305 | 0.090 |
Why?
|
Alleles | 4 | 2018 | 6898 | 0.080 |
Why?
|
Ischemia | 1 | 1998 | 1893 | 0.080 |
Why?
|
Case-Control Studies | 8 | 2022 | 22053 | 0.080 |
Why?
|
Pneumonia | 1 | 2020 | 2131 | 0.080 |
Why?
|
Societies, Medical | 4 | 2024 | 3905 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3804 | 0.080 |
Why?
|
Radiography | 3 | 2014 | 6965 | 0.080 |
Why?
|
Edema | 1 | 2012 | 769 | 0.080 |
Why?
|
Amino Acyl-tRNA Synthetases | 1 | 2009 | 88 | 0.080 |
Why?
|
Organ Specificity | 1 | 2013 | 1955 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 6 | 2018 | 17790 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20080 | 0.070 |
Why?
|
Health Behavior | 1 | 2018 | 2622 | 0.070 |
Why?
|
Double-Blind Method | 4 | 2022 | 12427 | 0.070 |
Why?
|
Primary Prevention | 1 | 2014 | 1207 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2012 | 2362 | 0.060 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1974 | 0.060 |
Why?
|
Consensus | 1 | 2013 | 3113 | 0.060 |
Why?
|
Antihypertensive Agents | 1 | 2013 | 2061 | 0.060 |
Why?
|
Prospective Studies | 7 | 2024 | 54303 | 0.060 |
Why?
|
Uridine Triphosphate | 1 | 2023 | 28 | 0.060 |
Why?
|
Hypertension | 2 | 2014 | 8594 | 0.060 |
Why?
|
Gene Frequency | 3 | 2018 | 3615 | 0.050 |
Why?
|
Retrospective Studies | 7 | 2024 | 80372 | 0.050 |
Why?
|
Genetic Loci | 1 | 2012 | 2618 | 0.050 |
Why?
|
Homocysteine | 2 | 1997 | 640 | 0.050 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 693 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2011 | 4541 | 0.050 |
Why?
|
Indoles | 2 | 2022 | 1829 | 0.050 |
Why?
|
United States | 7 | 2024 | 72461 | 0.050 |
Why?
|
Mucin-5B | 1 | 2022 | 147 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 4291 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2018 | 15789 | 0.050 |
Why?
|
Echocardiography | 1 | 2013 | 4981 | 0.050 |
Why?
|
Prognosis | 3 | 2017 | 29658 | 0.050 |
Why?
|
Electrocardiography | 1 | 2013 | 6414 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2022 | 65017 | 0.040 |
Why?
|
Aged, 80 and over | 7 | 2019 | 58995 | 0.040 |
Why?
|
Ulnar Nerve Compression Syndromes | 1 | 1999 | 23 | 0.040 |
Why?
|
Life Style | 2 | 2022 | 3896 | 0.040 |
Why?
|
Genotype | 4 | 2018 | 12960 | 0.040 |
Why?
|
Sulfides | 1 | 2000 | 171 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10181 | 0.040 |
Why?
|
Fever of Unknown Origin | 1 | 1999 | 94 | 0.040 |
Why?
|
Patient Care Team | 1 | 2010 | 2511 | 0.040 |
Why?
|
Haplotypes | 2 | 2017 | 2764 | 0.040 |
Why?
|
Ireland | 1 | 2019 | 172 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2000 | 431 | 0.040 |
Why?
|
Mass Screening | 2 | 2024 | 5423 | 0.040 |
Why?
|
ROC Curve | 2 | 2016 | 3568 | 0.040 |
Why?
|
Regression Analysis | 2 | 2020 | 6360 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2009 | 4357 | 0.040 |
Why?
|
Odds Ratio | 2 | 2022 | 9716 | 0.040 |
Why?
|
HLA-DP Antigens | 1 | 2017 | 28 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 933 | 0.040 |
Why?
|
Sex Factors | 3 | 2020 | 10547 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2023 | 894 | 0.040 |
Why?
|
Young Adult | 4 | 2017 | 58741 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15757 | 0.040 |
Why?
|
Peptides, Cyclic | 1 | 2019 | 392 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2023 | 1296 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1650 | 0.040 |
Why?
|
Temporal Arteries | 1 | 1998 | 148 | 0.030 |
Why?
|
Vascular Resistance | 1 | 2020 | 933 | 0.030 |
Why?
|
Idiopathic Interstitial Pneumonias | 1 | 2016 | 24 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10344 | 0.030 |
Why?
|
Genetic Variation | 1 | 2011 | 6551 | 0.030 |
Why?
|
Methionine | 2 | 1997 | 569 | 0.030 |
Why?
|
Pleural Effusion | 1 | 1999 | 342 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2018 | 786 | 0.030 |
Why?
|
Respiratory Mechanics | 1 | 2020 | 699 | 0.030 |
Why?
|
Cystathionine beta-Synthase | 1 | 1995 | 27 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14495 | 0.030 |
Why?
|
Axilla | 1 | 1998 | 626 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1668 | 0.030 |
Why?
|
Prevalence | 2 | 2023 | 15687 | 0.030 |
Why?
|
Gene Expression | 2 | 2018 | 7588 | 0.030 |
Why?
|
Age Factors | 3 | 2020 | 18416 | 0.030 |
Why?
|
Syndrome | 2 | 2013 | 3280 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2015 | 426 | 0.030 |
Why?
|
Angioplasty, Balloon | 1 | 1998 | 597 | 0.030 |
Why?
|
Neutrophils | 3 | 2017 | 3767 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 2 | 2022 | 5643 | 0.030 |
Why?
|
Cohort Studies | 5 | 2016 | 41335 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6771 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 14660 | 0.030 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2017 | 225 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2020 | 1843 | 0.030 |
Why?
|
Mesenteric Artery, Superior | 1 | 2014 | 95 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2392 | 0.030 |
Why?
|
Survival Rate | 2 | 2018 | 12808 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1765 | 0.030 |
Why?
|
Angiography | 1 | 1998 | 1605 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2015 | 377 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3696 | 0.030 |
Why?
|
Exercise Test | 1 | 2020 | 2128 | 0.030 |
Why?
|
Quality of Life | 2 | 2023 | 13308 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1636 | 0.020 |
Why?
|
Chemokines | 1 | 2015 | 962 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2013 | 877 | 0.020 |
Why?
|
Health Status | 1 | 2003 | 4081 | 0.020 |
Why?
|
Major Histocompatibility Complex | 1 | 2013 | 928 | 0.020 |
Why?
|
Time Factors | 1 | 2012 | 40165 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 24123 | 0.020 |
Why?
|
Massachusetts | 1 | 2022 | 8803 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 3224 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 1998 | 1869 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3817 | 0.020 |
Why?
|
China | 1 | 2015 | 2339 | 0.020 |
Why?
|
Raynaud Disease | 1 | 2009 | 79 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2013 | 1697 | 0.020 |
Why?
|
Motivation | 1 | 2018 | 1993 | 0.020 |
Why?
|
Receptors, Fc | 1 | 2011 | 534 | 0.020 |
Why?
|
Comorbidity | 1 | 2022 | 10551 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13314 | 0.020 |
Why?
|
Monocytes | 1 | 2017 | 2575 | 0.020 |
Why?
|
Databases, Factual | 1 | 2023 | 8035 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1433 | 0.020 |
Why?
|
Inflammation | 2 | 2020 | 10756 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1999 | 2159 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2009 | 585 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 21392 | 0.020 |
Why?
|
Face | 1 | 2012 | 1017 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2017 | 12626 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2013 | 2192 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2023 | 4775 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12531 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2011 | 2651 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2717 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 1599 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4742 | 0.010 |
Why?
|
Graft Rejection | 1 | 2016 | 4426 | 0.010 |
Why?
|
Hand | 1 | 2009 | 903 | 0.010 |
Why?
|
Arthritis | 1 | 2009 | 666 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5787 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10790 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 13981 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8624 | 0.010 |
Why?
|
Models, Genetic | 1 | 2011 | 3442 | 0.010 |
Why?
|
Fever | 1 | 2009 | 1617 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2011 | 2093 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2014 | 39261 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22023 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16546 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8482 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42063 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18137 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9287 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2012 | 11071 | 0.010 |
Why?
|
Antibodies, Antinuclear | 1 | 1999 | 344 | 0.010 |
Why?
|
Vision Disorders | 1 | 2003 | 1084 | 0.010 |
Why?
|
Vitamin B 12 Deficiency | 1 | 1997 | 119 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6465 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15289 | 0.010 |
Why?
|
Genomics | 1 | 2011 | 5794 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2003 | 2417 | 0.010 |
Why?
|
Adolescent | 2 | 2013 | 87810 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1997 | 522 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81208 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11712 | 0.010 |
Why?
|
Fasting | 1 | 1997 | 1603 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 25942 | 0.010 |
Why?
|
Animals | 1 | 2018 | 167963 | 0.000 |
Why?
|